FEP Benefits Changes for Infliximab, Effective Jan. 1, 2019

Posted October 22, 2018

The autoimmune drug infliximab will be covered as a medical benefit for Blue Cross and Blue Shield Federal Employee Program® (FEP) members who receive their first infusion on or after Jan. 1, 2019.

Now, FEP members may receive infliximab under either pharmacy or medical benefits, as follows:.

  • Members currently receiving infliximab under pharmacy benefits will continue to receive it under pharmacy benefits after Jan. 1, 2019. FEP will notify these members.
  • If a member receiving infliximab prior to Jan. 1, 2019, changes FEP benefit plans or health insurers, they will receive the drug under medical benefits, regardless of how they previously received it.

Infliximab brand names are Remicade, Inflectra and Renflexis. It is an intravenous antibody that is used to treat many life-long inflammatory health problems.

Third party brand names are the property of their respective owners.